Fig. 2
mRNA expression analysis ofNT5Ein normal lung tissues and LUAD tissues. (A) Differential expression of NT5E between tumors and normal samples using combined data from TCGA-LUAD and GTEx datasets. (B) Increased expression of NT5E in LUAD compared to normal tissues in the GEPIA database. (C)NT5E expression in LUAD was examined by using the UALCAN database. (D) Analysis of NT5E expression in LUAD and adjacent normal tissues in the TCGA-LUAD database. (E) Statistical analyses of NT5E expression in 58 pairs of LUAD tissues and adjacent normal tissues in the TCGA database. (F) Statistical analyses of NT5E expression in normal lung tissues and LUAD tissues in Biomarker Exploration of Solid Tumors (BEST) database. (G–J) Box plots represent the mRNA expression and promoter methylation levels of the NT5E gene across various LUAD patient cohorts, categorized by clinical parameters, utilizing data from the UALCAN portal. The analysis was stratified by sex (G), cancer stage (H), presence of metastasis (I), and TP53 mutation status (J). Lymph node metastasis was classified according to the number of involved axillary lymph nodes: N0 for no metastasis, N1 for 1 to 3 nodes, N2 for 4 to 9 nodes, and N3 for 10 or more nodes. * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001.
